Obamacare pushing us back into the dark ages of medicine.

Obamacare plans are controlling costs by limiting patients’ access to more expensive — and possibly more effective — drugs, according to revelations made at a Capitol Hill hearing Thursday.

Plans on the Affordable Care Act (ACA) exchanges are “limiting the formulary” of drugs provided to patients to exclude expensive treatments for diseases including rheumatoid arthritis, according to House Energy and Commerce subcommittee testimony Thursday from William F. Harvey, government affairs committee chairman at the American College of Rheumatology.

“Similar to ongoing changes to provider networks, another rampant practice that has been in existence for some time, but has now increased within exchange plans, is changes in formulary coverage of medications,” Harvey stated in prepared testimony.

Continue reading →